



Article type : B - Brief Communication

COVID-19 and Kidney Transplantation: Results from the TANGO International Transplant Consortium

Paolo Cravedi¹, Suraj Sarvode Mothi², Yorg Azzi³, Meredith Haverly¹,
Samira Farouk⁴, María José Pérez-Sáez⁵, Maria Dolores Redondo-Pachón⁵, Barbara Murphy¹,
Sander Florman⁴, Laura Goldfarb Cyrino², Monica Grafals⁶, Sandheep Venkataraman⁶, Xingxing
Shelley Cheng⁷, Aileen Xinqian Wang⁷, Gianluigi Zaza⁸, Andrea Ranghino⁹, Lucrezia Furian¹⁰,
Joaquin Manrique¹¹, Umberto Maggiore¹¹, Ilaria Gandolfini¹², Nikhil Agrawal¹³, Het Patel¹³, Enver
Akalin³, Leonardo V. Riella² for the TANGO study group

¹ Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York

² Schuster Transplantation Research Center, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts

³ Division of Nephrology, Montefiore Medical Center Transplant Center, Albert Einstein College of Medicine, Bronx, New York

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/AJT.16185](https://doi.org/10.1111/AJT.16185)

This article is protected by copyright. All rights reserved

⁴ *Recanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York*

⁵ *Servicio de Nefrología, Hospital del Mar, Barcelona, Spain*

⁶ *Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado*

⁷ *Stanford University School of Medicine, Department of Medicine, Division of Nephrology, Stanford, Massachusetts*

⁸ *Renal Unit, Department of Medicine, University Hospital of Verona, Italy*

⁹ *SOD Nefrologia, Dialisi e Trapianto Rene, AOU Ospedali Riuniti, Ancona, Italy*

¹⁰ *Kidney and Pancreas Transplantation Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Italy*

¹¹ *Nephrology Service, Complejo Hospitalario de Navarra, Pamplona, Spain*

¹² *Dipartimento di Medicina e Chirurgia, Università di Parma, UO Nefrologia, Azienda Ospedaliera-Universitaria Parma, Parma, Italy*

¹³ *Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts*

Paolo Cravedi and Suraj Sarvode Mothi are co-first authors.

Enver Akalin and Leonardo V. Riella are co-senior authors.

Correspondence

Paolo Cravedi

paolo.cravedi@mssm.edu

Leonardo V. Riella

lriella@bwh.harvard.edu

Abbreviations: COVID-19: coronavirus disease 2019, ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; MMF: mycophenolate mofetil.

ABSTRACT

Kidney transplant recipients may be at high risk of developing critical COVID-19 illness due to chronic immunosuppression and comorbidities. We identified hospitalized adult kidney transplant recipients at 12 transplant centers in the US, Italy and Spain who tested positive for COVID-19. Clinical presentation, laboratory values, immunosuppression and treatment strategies were reviewed and predictors of poor clinical outcomes were determined through multivariable analyses. Among 9,845 kidney transplant recipients across centers, 144 were hospitalized due to COVID-19 during the 9-week study period. 65% were male with a mean age of 60 (± 12) years, 40% Hispanic and 25% African-American. Prevalent comorbidities included hypertension (95%), diabetes (52%), obesity (49%), heart (28%) and lung (19%) disease. Therapeutic management included antimetabolite withdrawal (68%), calcineurin inhibitor withdrawal (23%), hydroxychloroquine (71%), antibiotics (74%), tocilizumab (13%) and antivirals (14%). During a median follow-up period of 52 days (IQR: 16-66 days), acute kidney injury occurred in 52% cases, respiratory failure requiring intubation in 29%, and mortality was 32%. The 44 patients who died were older, had lower lymphocyte counts and eGFR, higher serum lactate dehydrogenase, procalcitonin and IL-6 levels. In sum, hospitalized kidney transplant recipients with COVID-19 have higher rates of acute kidney injury and mortality.

INTRODUCTION

Since its initial detection in Wuhan, China, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is responsible for coronavirus disease 2019 (COVID-19), has rapidly emerged as an international pandemic (1, 2). As of June 2020, more than 6 million cases have been reported worldwide, leading to more than 400,000 deaths. Clinical symptoms associated with COVID-19 are variable though the most common include fever, cough, shortness of breath, diarrhea, anosmia and lack of taste (2). Those with advanced age and medical comorbidities including diabetes mellitus, hypertension, cardiovascular disease, pulmonary disease and malignancy are at increased risk for severe disease, including pneumonia, acute respiratory distress syndrome, septic shock, multi-organ failure, and death (3, 4). In addition, a hyper-inflammatory state has been described with COVID-19 infection, known as cytokine storm syndrome, that is associated with rapidly worsening clinical features leading to multi-organ failure (5). Increased levels of circulating inflammatory cytokines, including IL-1, IL-6, and IFN gamma have been shown in those patients (2, 4, 5).

Theoretically, solid organ transplant recipients are at particularly higher risk of developing critical COVID-19 due to chronic immunosuppression. European experience in Italy regarding 20 kidney transplant recipients with COVID-19 pneumonia documented a fast progression in more than 75% of their patients with 25% mortality during a median follow-up of 7 days (6). In Spain, 18 solid organ recipients diagnosed with COVID-19 had mortality rate of 28% (7). In the USA, the initial experience was reported by transplant centers in New York. A single center experience at Montefiore Medical Center reported 28% mortality in 36 consecutive adult kidney transplant recipients (8). Seventy-eight% required hospital admission, 96% of hospitalized patients had imaging findings of viral pneumonia, 39% required mechanical ventilation and 21% renal replacement therapy (8). Columbia and Cornell Medical Centers in New York reported clinical outcomes of 90 transplant recipients (46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants) (9). Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. Northwell center reported 30% mortality and 50% acute kidney injury in 10 kidney transplant recipients (10).

The aim of our report is to present the clinical outcomes of a large multicenter cohort of 144 kidney transplant recipients who were hospitalized due to COVID-19 at 12 transplant centers in North America and Europe to identify predictors of poor clinical outcomes.

MATERIALS AND METHODS

Study design and participants

This retrospective cohort study included kidney transplant recipients admitted with COVID-19 in 12 centers participating in the international TANGO consortium (www.tangoxstudy.com).¹ We included all adult (> 18 years) kidney transplant recipients with a functioning kidney allograft who were admitted to a hospital between March 2nd and May 15th, 2020. Medical records were reviewed by TANGO investigators in the collaborating centers. Since testing criteria for SARS-CoV-2 is variable in different locations, we have decided to exclude patients with presumed or diagnosed COVID-19 that did not require hospital admission. We also excluded any patients that had been reported in prior publications by any of the participating centers. The study was approved by the Brigham and Women's Hospital Research Ethics Commission (2015P000993).

Data collection

Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records using an ad hoc designed data collection form. All data were checked for quality by two physicians (PC and LVR) and a third researcher (SSM).

Laboratory procedures

SARS-CoV-2 infection was determined in nasopharyngeal swabs by real-time RT-PCR. Routine blood examinations performed included complete blood count, coagulation profile, serum biochemical tests (including renal and liver function, creatine kinase, lactate dehydrogenase (LDH), and electrolytes), myocardial enzymes, interleukin-6 (IL-6), serum ferritin, C-reactive protein, D-dimer, and procalcitonin. Frequency of examinations was determined by the treating physician in each center. Fever was defined as an axillary temperature of at least 37.3 C. Dyspnea was defined as a subjective experience of breathing discomfort reported by the patient. Acute kidney injury was diagnosed according to the KDIGO clinical practice guidelines.

Statistical analysis

Descriptive statistics for Table 1 include frequency analysis (counts and percentages) for categorical variables and medians and interquartile ranges (IQRs) for continuous measures. Distributions were visually inspected for all continuous measures, and potential influence points/outliers double-checked with respective sites for validity. Due to the small sample, we used the non-parametric Mann-Whitney U test for all continuous variables and χ^2 test or Fisher exact test (for cell size < 5) for all categorical variables. All variables evaluated for missing data and the little's test for the overall sample did not reject the null hypothesis confirming MCAR (Missing Completely At Random). Sensitivity analysis by repeating all tests without missing data verified no change in results. Univariate and multivariate logistic regression models were used to explore associations of baseline laboratory and clinical characteristics and the risk for death. At the outset, it was decided to exclude any COVID-19-related case management characteristics for investigating predictors of survival outcomes (e.g., CNI withdrawal, Hydroxychloroquine). Therefore, only clinical or laboratory variables demonstrating significant differences from the baseline Table 1 were candidates for univariate regression models predicting survival.

With the intention of parsimony due to the limited sample size, we attempted a multivariable risk-prediction model using only five vital predictors from the univariable models. Although a strong predictor, dyspnea was excluded due to collinearity with respiratory rate. Model fit and superiority for the multivariable model was evaluated using the Akaike information criterion and the Nagelkerke pseudo R^2 . A type-1 error rate of 0.05 was considered statistically significant for all analyses. Statistical analysis was performed using the R software [version 3.6.1 (2019-07-05)].

RESULTS

Patients' characteristics

144 kidney transplant recipients with a diagnosis of COVID-19 were identified. Out of 144 patients, 95 (66%) were male with a median age of 62 (IQR 52-69) (56.2% more than 60) years old, 40% Hispanics, 31% Caucasians, and 25% African Americans and (Table 1). Hypertension was the most common comorbidity affecting 95% of patients, followed by diabetes (52%), obesity (49%), heart disease (28%) and lung disease (19%). 28% had a prior or current history of smoking tobacco, while 15% had a history of cancer. 24 patients (17%) were receiving angiotensin II receptor antagonists at the time of diagnosis and 20 (14%) were taking angiotensin converting enzyme inhibitors.

Time to diagnosis of COVID-19 after transplantation ranged from < 1 year to 31 years (median 5 years); 16% were diagnosed during the first year after transplantation. Causes of original kidney disease included diabetes (30%), glomerular disease (17%), hypertension (14%), and polycystic kidney disease (9%). The majority of patients had undergone a deceased kidney transplant (78%) and received induction therapy with T-cell depletion at the time of transplant (62%). Maintenance immunosuppression consisted of tacrolimus (91%), antimetabolite (mycophenolate) (77%), mTOR inhibitor (7.5%) and steroids (86%).

Clinical outcomes

The most common symptoms on admission were fever and dyspnea (67%), followed by myalgia (53%) and diarrhea (38%) (Table 2). During a median follow-up of 52 days (IQR: 16-66 days) after the diagnosis of the first COVID-19 patient, 74 patients developed acute kidney injury (51%), 42

patients required mechanical ventilation (29%), 46 patients had died, totaling 32% mortality in this cohort. Twenty-two out of the patients who entered ICU died (51%). The median time from illness onset (ie, before admission) to discharge was 22 days (IQR 15 – 35 days), whereas the median time to death was 15 days (IQR: 8 – 22 days; Table 1). Extracorporeal membrane oxygenation was used in three patients, none of whom survived.

Risk factors associated with death from COVID-19

There was no difference in mortality across the transplant centers. Patients who died were older than survivors (66 vs 60 years old; $p < 0.001$), with 71% of patients over the age of 60 among non-survivors (Table 1). There was no significant difference in outcomes between recipients of organs from living or deceased donors, nor between patients with less than 1 year since transplant compared to those with longer time since transplant (Table 1). Time from onset of symptoms to admission was slightly shorter in patients who died. Neither race, comorbidities, induction therapy with depleting agents, maintenance immunosuppression nor therapy with RASi differed significantly between survivors and non-survivors (Table 1).

Presentation and laboratory results according to mortality from COVID-19

The respiratory rate at admission was significantly higher in non-survivors compared to survivors (Table 2) and diarrhea was less frequent in non-survivors (23.9% vs 44.9%). None of the other clinical characteristics at presentation differed significantly between the two groups. Major laboratory markers were tracked from illness onset. Lymphopenia (< 0.8) was present in 42% of patients. Baseline lymphocyte count was significantly higher in survivors than non-survivors (1.2 vs 0.7, $p = 0.004$) as well as estimated GFR (53 vs 38 mL/min) (Table 2). There was no statistically significant difference between the 2 groups in terms of white blood cell, hemoglobin, platelet, alanine aminotransferase, and creatine phosphokinase levels but non-survivors had higher aspartate transaminase (30 u/L vs. 24 u/L) and LDH (406 U/L vs. 296 U/L, $p < 0.001$) levels. In terms of inflammatory markers, levels of procalcitonin (0.61 ng/ml vs 0.2 ng/ml, $p = 0.003$) and IL-6 (79.94 ng/ml vs 24.80 ng/ml, $p = 0.007$) were significantly elevated in non-survivors compared with survivors (Table

2), while ferritin, D-Dimer, and C-reactive protein levels were not significantly different between groups.

Treatment of COVID-19 in kidney transplant recipients

In most cases, mycophenolate (MMF/MPA) or everolimus were reduced or discontinued (68%), while calcineurin inhibitor were discontinued in 32 patients (23%) (Table 3). There was no significant association between immunosuppression withdrawal and mortality. Majority of patients received hydroxychloroquine (71%) and antibiotics (74%), while a smaller subset of patients received tocilizumab (13%) or antivirals (14%) (Figure 1). There was no significant difference in mortality among different treatments of COVID-19 with the exception of slight higher use of antibiotics in non-survivors.

Predictors of mortality

In univariable analysis, odds of in-hospital death was higher in older patients, patients with higher respiratory rate, LDH, IL-6 and procalcitonin levels, while mortality risk was lower in patients with diarrhea or higher eGFR. These variables were used for the multivariable logistic regression model. In addition to age, we found that higher respiratory rate, lower eGFR and higher IL-6 at admission were associated with increased odds of death (Table 4).

DISCUSSION

Our large international registry demonstrated a high early mortality rate of 32% in hospitalized kidney transplant recipients with COVID-19 similar to previous single-center reports, which observed death rates between 24-30% (6-10). Our kidney transplant patients had multiple risk factors for COVID-19-related mortality, other than chronic immunosuppressive treatment, that have been shown to be important predictors in the general population. These risk factors include older age, hypertension, diabetes mellitus and cardiovascular disease (1, 3, 4). It is still not clear if immunosuppressive treatment is an independent risk factor on top of all the other medical

comorbidities. Mortality rate from COVID-19 disease in the general population has been reported at 8% in New York, 14% in Italy and 12% in Spain (<https://coronavirus.jhu.edu/map.html>). In hospitalized patients, the mortality rate in the general population varies. In initial study from China, it was reported a 28% mortality in 191 patients (1). Clinical outcomes were assessed for 2634 patients who were discharged or had died among 5700 hospitalized patients in New York area (3). The authors reported 21% mortality with 12.2% of patients receiving invasive mechanical ventilation and 3.2% treated with kidney replacement therapy. Mortality for those requiring mechanical ventilation was 88.1%. In another cohort of 1150 adults who were admitted with laboratory-confirmed COVID-19 in a New York Hospital, of which 257 (22%) were critically ill, 39% of patients had died, 79% patients received mechanical ventilation and 31% renal replacement therapy (4). Older age, chronic heart and lung disease, high IL-6 and D-Dimer levels were associated with mortality. Lastly, an initial report from Seattle documented 50% mortality in 24 patients admitted to the intensive care unit (11), similar to our mortality rate (51%).

In our cohort, 47 patients from Montefiore Medical Center, Bronx had the highest mortality (40%). Previous report from the same center reported 29% mortality in 28 hospitalized patients during a shorter follow-up. The main difference from other centers is that 89% of Bronx transplant patients were African-American and Hispanic. A recent study reported that, the Bronx, which has the highest proportion of racial/ethnic minorities, greater number of people living in poverty, and lowest levels of educational attainment had higher rates of hospitalization and death related to COVID-19 compared to other NYC boroughs, despite having the lowest proportion of patients with age greater than 65 years old, indicating the potential importance of social and economic factors (12).

Acute kidney injury is common in patients with COVID-19 due to multiple factors including reduced renal perfusion, multiorgan failure, and cytokine storm. Although range across centers is wide (3, 4, 13) and later reports showed higher incidence of AKI, our data indicate that mortality and the burden of AKI in the transplant population is substantial and at the highest end range of estimates. Interestingly, immunohistochemistry studies of postmortem analysis showed that SARS-CoV-2 NP antigen was accumulated in kidney tubules. Viral infection not only induces CD68⁺ macrophages infiltration into tubulointerstitium, but also enhances complement C5b-9 deposition on tubules. It has been suggested that the virus may trigger direct cytopathic changes in the kidney (14, 15), though it is unclear what proportions of patients may develop AKI due to direct SARS-Cov2 pathology versus a consequence of acute tubular injury from cytokine storm, reduction in effective arterial circulating

volume and multi-organ failure.

Supportive care remains the mainstay of treatment for COVID-19 and there are currently no antiviral therapies with proven efficacy. There is an absence of consensus about how to adjust immunosuppression in COVID-19 kidney transplant recipients. Reduction of the dosage of calcineurin inhibitors and reduction or withdrawal of anti-metabolite was considered in patients with COVID-19. However, reduction of immunosuppression could hypothetically exacerbate inflammation in the absence of anti-inflammatory agents. The majority of our patients were treated with hydroxychloroquine, an anti-malarial medication with in vitro activity against SARS-CoV-2. However, recent evidence from a large observational study (16) and a randomized controlled trial (17) generated after inclusion of patients in our registry does not support a significant benefit of this drug for treatment or prophylaxis of COVID-19. Lopinavir/ritonavir, was also frequently used in patients with COVID-19, based on data suggesting efficacy against another coronavirus, Middle East respiratory syndrome (18). However, Cao et al. found no benefit of lopinavir/ritonavir in hospitalized patients with COVID-19 infection (19). Another antiviral agent, remdesivir, is an adenosine analogue that has shown in vitro activity against other coronaviruses. In a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with COVID-19 documented faster recovery time (11 vs 15 days) and reduced mortality by 14 days (7.1% vs 11.9% in placebo; hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04) (20). However, another randomized trial conducted in China did not document any clinical benefit of remdesivir (21). Due to limited number of patients in our study (n=9), we cannot assess any efficacy of this drug.

Interleukin-6 levels (IL-6) and procalcitonin were markedly elevated in transplant recipients with severe COVID-19 disease (8). Many large observational studies including COVID-19 patients from the general population also identified IL-6 as a major risk factor for mortality. Tocilizumab is a humanized monoclonal antibody that blocks the IL-6 receptor, which is thought to help attenuate the overstimulated immune response associated with COVID-19 infection. However, published efficacy data of tocilizumab is limited to 21 COVID-19 patients (22). A multicenter phase 2 trial with tocilizumab is currently underway.

Procalcitonin is a peptide released in the setting of systemic inflammation, in particular bacterial infections, and the magnitude of elevation has correlated with infection severity (23). Procalcitonin synthesis is triggered by bacterial endotoxin (24) and systemic cytokines such as TNF-alpha, IL-1-beta and IL-6 (25, 26). While procalcitonin has been proposed by some as a

Accepted Article
biomarker to differentiate bacterial from viral infections, multiple recent studies in COVID-19 patients documented a correlation of procalcitonin with disease severity (1). It is highly likely that the increased procalcitonin levels correlate with the cytokine storm triggered by SARS-Cov-2. Another possibility is that it represents a bacterial co-infection, though further studies are needed to clarify that. The general recommendations are not to use procalcitonin to guide antibiotic use at this time (27).

A D-Dimer level of more than 1ug/mL has been associated with poor prognosis in setting of COVID-19 (1). In a retrospective study of 183 patients with COVID-19 pneumonia, 71.4% of nonsurvivors had high grade of disseminated intravascular coagulation with 85.7% having a D-Dimer level > 3 ug/mL (28). In our study, D-dimer levels were, on average, higher than 1ug/mL, but did not significantly differ between kidney transplant recipients who died and those who survived, possibly as a consequence of ongoing immunosuppression or intrinsic unique characteristics of this cohort of individuals.

Our multicenter study has several limitations. Individual centers had different approaches and access to medications for the treatment of COVID-19. Therefore, it is difficult to compare treatments and our data reflects real-world use and outcomes of kidney transplant recipients with COVID-19. In addition, we have only focused on a homogenous cohort of hospitalized kidney transplant recipients, since criteria for diagnosis of COVID-19 in the ambulatory setting was variable and many patients did not have documented follow-up information from centers. Overall, this selection criteria limits the generalizability of our findings and prevents any conclusion about the overall mortality of all kidney transplant patients but only of hospitalized patients.

One other notable limitation of the study is the small sample and retrospective method, which may have resulted in false-positives, or over-estimation. We wish to emphasize the exploratory nature of the study, which was not driven by formal hypotheses but would instead hope that the findings presented here will inform larger studies going forward.

In conclusion, kidney transplant recipients should be closely monitored as they appear to have a high mortality and AKI rate. Investigation of the best strategy of immunosuppression adjustment upon COVID-19 will be needed.

DISCLOSURE

The authors of this manuscript have no conflicts of interest to disclose as described by the *American Journal of Transplantation*.

ORCID:

Paolo Cravedi: orcid.org/0000-0001-7837-0923

Leonardo V. Riella: orcid.org/0000-0002-7636-3196

FIGURE LEGEND

Figure 1. Percentages of patients receiving various COVID-19-related therapies stratified by survivors (red) and non-survivors (green). HCQ; hydroxychloroquine.

REFERENCES

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-62.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
3. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020.
4. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet*. 2020;395(10239):1763-70.
5. Ye Q, Wang B, Mao J. Cytokine Storm in COVID-19 and Treatment. *J Infect*. 2020.
6. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. *Kidney international*. 2020.
7. Fernandez-Ruiz M, Andres A, Loinaz C, Delgado JF, Lopez-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020.
8. Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, et al. Covid-19 and Kidney Transplantation. *N Engl J Med*. 2020.
9. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020.
10. Nair V, Jandovitz N, Hirsch JS, Nair G, Abate M, Bhaskaran M, et al. COVID-19 in kidney transplant recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020.
11. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J Med*. 2020.

12. Wadhera RK, Wadhera P, Gaba P, Figueroa JF, Joynt Maddox KE, Yeh RW, et al. Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. *JAMA*. 2020.
13. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney international*. 2020.
14. Bo Diao CW, Rongshuai Wang, Zeqing Feng, Yingjun Tan, Huiming Wang, Changsong Wang, Liang Liu, Ying Liu, Yueping Liu, Gang Wang, Zilin Yuan, Liang Ren, Yuzhang Wu, Yongwen Chen. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. 2020.
15. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. *Journal of the American Society of Nephrology : JASN*. 2020.
16. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020.
17. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med*. 2020.
18. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. *Antivir Ther*. 2016;21(5):455-9.
19. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020;382(19):1787-99.
20. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med*. 2020.
21. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2020;395(10236):1569-78.
22. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci U S A*. 2020;117(20):10970-5.
23. Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. *Swiss Med Wkly*. 2001;131(41-42):595-602.
24. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. *J Clin Endocrinol Metab*. 1994;79(6):1605-8.
25. Becker KL, Nylen ES, White JC, Muller B, Snider RH, Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab*. 2004;89(4):1512-25.

26. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. *Physiol Res.* 2000;49 Suppl 1:S57-61.
27. Metlay JP, Waterer GW. Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. *Ann Intern Med.* 2020.
28. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844-7.

Table 1. Baseline demographics, comorbidities and medications of hospitalized kidney transplant recipients with COVID-19.

	Total (n=144)	Survivors (n=98)	Non-Survivors (n=46)	p value
Baseline characteristics				
Age	62.00 [52.00, 69.00]	60.00 [48.00, 66.75]	66.50 [60.00, 72.00]	<0.001
>60 yrs	81 (56.2%)	48 (49.0%)	33 (71.7%)	0.012
Male	94 (65.3%)	65 (66.3%)	29 (63.0%)	0.711
Race				0.99*
Hispanic	56 (39.7%)	39 (40.2%)	17 (38.6%)	
Caucasian	43 (30.5%)	29 (29.9%)	14 (31.8%)	
African American	35 (24.8%)	24 (24.7%)	11 (25.0%)	
Others	7 (5.0%)	5 (5.2%)	2 (4.5%)	
Causes of kidney disease				
				0.96*
Diabetes Mellitus	43 (30.1%)	28 (28.9%)	15 (32.6%)	
Glomerular	25 (17.5%)	17 (17.5%)	8 (17.4%)	
Hypertension	20 (14.0%)	14 (14.4%)	6 (13.0%)	
Others	24 (16.8%)	17 (17.5%)	7 (15.2%)	
Polycystic kidney disease	13 (9.1%)	10 (10.3%)	3 (6.5%)	
Unknown	18 (12.6%)	11 (11.3%)	7 (15.2%)	
Type of kidney transplant (deceased vs living donor)				
Deceased	112 (77.8%)	75 (76.5%)	37 (80.4%)	0.756
Time from transplant to COVID-19 symptom onset (years)				
< 1 year since transplant to COVID-19 symptom onset	23 (16.0%)	17 (17.3%)	6 (13.0%)	0.629
Transplant center				
				0.4*
Bronx, NY	47 (32.6%)	28 (28.6%)	19 (41.3%)	
New York, NY	29 (20.1%)	21 (21.4%)	8 (17.4%)	
Palo Alto, CA	4 (2.8%)	4 (4.1%)	0 (0.0%)	
Denver, CO	11 (7.6%)	8 (8.2%)	3 (6.5%)	
Boston, MA	11 (7.6%)	10 (10.2%)	1 (2.2%)	
Barcelona, SP	24 (16.7%)	15 (15.3%)	9 (19.6%)	
Navarra, SP	3 (2.1%)	3 (3.1%)	0 (0.0%)	

Parma, IT	5 (3.5%)	2 (2.0%)	3 (6.5%)
Padova, IT	3 (2.1%)	2 (2.0%)	1 (2.2%)
Ancona, IT	5 (3.5%)	3 (3.1%)	2 (4.3%)
Verona, IT	2 (1.4%)	2 (2.0%)	0 (0.0%)

Comorbidities

Hypertension	137 (95.1%)	93 (94.9%)	44 (95.7%)	1
Diabetes [#]	75 (52.1%)	50 (51.0%)	25 (54.3%)	0.724
Obesity	71 (49.3%)	45 (45.9%)	26 (56.5%)	0.284
Heart disease	41 (28.5%)	23 (23.5%)	18 (39.1%)	0.074
Lung disease	27 (18.8%)	18 (18.4%)	9 (19.6%)	1
Cancer	22 (15.4%)	12 (12.4%)	10 (21.7%)	0.213
Smoker (current or past)	39 (28.5%)	25 (26.9%)	14 (31.8%)	0.55
HIV/AIDS	3 (2.5%)	1 (1.2%)	2 (5.4%)	0.224

Medications

T-Cell depletion at time of transplant	85 (62.5%)	60 (65.9%)	25 (55.6%)	0.263
Tacrolimus	131 (91.0%)	91 (92.9%)	40 (87.0%)	0.349
MMF	111 (77.1%)	75 (76.5%)	36 (78.3%)	1
Everolimus	11 (7.6%)	6 (6.1%)	5 (10.9%)	0.329
Prednisone	125 (86.8%)	85 (86.7%)	40 (87.0%)	1
ARB	24 (16.7%)	17 (17.3%)	7 (15.2%)	0.815
ACE inhibitors	20 (13.9%)	14 (14.3%)	6 (13.0%)	1
Flu vaccination	78 (63.4%)	54 (63.5%)	24 (63.2%)	1

ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; MMF: mycophenolate mofetil. All data reported are median (IQR), n (%), or n/N (%). p-values reported result from the Mann-Whitney U test for continuous variables, and χ^2 test or Fisher's exact test (for cell counts < 5) for categorical variables. *Omnibus χ^2 /Fisher's exact test for all subgroups. [#]One patient had type 1 diabetes.

Table 2. Symptoms, laboratory findings and outcomes of hospitalized kidney transplant recipients with COVID-19.

	Total (n=144)	Survivors (n=98)	Non-Survivors (n=46)	p value
Time from symptom onset to admission (Days)	6.00 [3.00, 8.00]	6.00 [3.00, 9.00]	5.00 [2.00, 7.00]	0.053
Fever	96 (67.1%)	66 (68.0%)	30 (65.2%)	0.849
Myalgia	76 (53.1%)	48 (49.5%)	28 (60.9%)	0.215
Dyspnea	97 (67.8%)	59 (60.8%)	38 (82.6%)	0.012
Diarrhea	55 (38.2%)	44 (44.9%)	11 (23.9%)	0.017
Respiratory rate \geq 20	86 (65.6%)	50 (54.9%)	36 (90.0%)	<0.001
Heart rate	90.00 [80.00, 104.00]	91.00 [80.00, 104.75]	90.00 [84.50, 102.00]	0.781
Systolic blood pressure	127.00 [115.25, 140.00]	126.00 [117.00, 137.50]	128.00 [114.50, 155.00]	0.428
Diastolic blood pressure	72.00 [63.25, 80.00]	72.00 [64.50, 80.00]	72.00 [63.00, 82.00]	0.978
LABORATORY VALUES				
White blood cell count, $\times 10^9$ per L	6.40 [4.60, 8.31]	5.95 [4.60, 7.77]	7.00 [5.35, 9.62]	0.162
Lymphocyte count, $\times 10^9$ per L	0.94 [0.50, 3.08]	1.20 [0.60, 4.08]	0.71 [0.40, 1.10]	0.004
Hemoglobin, gm/dL	11.90 [10.30, 13.20]	11.90 [10.60, 13.60]	11.65 [10.25, 13.00]	0.333
Platelet count, $\times 10^9$ per L	178.00 [133.50, 236.75]	183.50 [144.50, 236.75]	166.00 [109.50, 237.00]	0.157
Baseline creatinine, mg/dL	1.50 [1.10, 1.90]	1.40 [1.00, 1.80]	1.60 [1.30, 2.00]	0.022
eGFR	48.88 [32.96, 66.21]	53.54 [39.15, 70.48]	37.97 [29.76, 52.03]	0.001
Aspartate transaminase, u/L	26.00 [20.00, 36.25]	24.00 [20.00, 34.00]	30.00 [21.00, 45.75]	0.045
Alanine aminotransferase	20.00 [12.00, 29.00]	20.00 [12.00, 28.75]	20.00 [14.25, 28.75]	0.594
Lactate dehydrogenase, u/L	317.00 [261.00, 408.25]	296.00 [245.00, 368.00]	406.00 [292.00, 474.00]	<0.001
Creatine phosphokinase, u/L	83.00 [47.00, 153.00]	78.00 [47.00, 134.00]	107.50 [46.25, 198.75]	0.309
C-reactive protein, mg/L	41.00 [11.50, 125.35]	41.00 [10.80, 103.00]	44.40 [12.95, 170.90]	0.21
Serum ferritin, μ g/L	1260.00 [525.50, 2620.00]	1257.50 [410.25, 2819.25]	1544.00 [629.00, 2296.00]	0.594
D-dimer, μ g/mL	1.12 [0.62, 2.00]	1.08 [0.54, 1.92]	1.17 [0.80, 2.24]	0.171
IL-6, ng/ml.	36.92 [8.05, 94.81]	24.80 [5.03, 64.10]	76.94 [14.43, 194.35]	0.007
Procalcitonin, ng/mL	0.30 [0.10, 1.03]	0.20 [0.10, 0.57]	0.61 [0.21, 2.43]	0.003

All data reported are median (IQR), n (%), or n/N (%). p-values reported result from the Mann-Whitney U test for continuous variables, and χ^2 test or Fisher's exact test (for cell counts < 5) for categorical variables. *Omnibus χ^2 /Fisher's exact test for all subgroups.

Accepted Article

Table 3. Outcomes and management of hospitalized kidney transplant recipients with COVID-19.

	Total (n=144)	Survivors (n=98)	Non-Survivors (n=46)	p value
Respiratory failure requiring intubation	42 (29.2)	19 (19.4)	23 (50.0)	<0.001
Acute kidney injury	74 (52.1)	48 (49.0)	26 (59.1)	0.282
Tacrolimus withdrawal	32 (22.9)	18 (18.9)	14 (31.1)	0.133
MMF or Everolimus withdrawal	91 (67.9)	59 (64.8)	32 (74.4)	0.324
Increased steroids	95 (66.0)	64 (65.3)	31 (67.4)	0.852
Hydroxychloroquine	101 (70.6)	65 (66.3)	36 (80.0)	0.115
Antibiotics	106 (74.1)	66 (68.0)	40 (87.0)	0.023
Tocilizumab	19 (13.4)	11 (11.3)	8 (17.8)	0.301
Remdesivir	9 (6.3)	6 (6.1)	3 (6.7)	1
Lopinavir-Ritonavir	7 (4.9)	3 (3.1)	4 (8.9)	0.206
Darunavir-Ritonavir	3 (2.1)	2 (2.0)	1 (2.2)	1
Darunavir-Cobicistat	1 (0.7)	0 (0.0)	1 (2.2)	0.315

All data reported are median (IQR), n (%), or n/N (%). % values reported exclude missing data. p-values reported result from the Mann-Whitney U test for continuous variables, and χ^2 test or Fisher's exact test (for cell counts < 5) for categorical variables.

